- Home
- TNGX vs NTLA Comparison
TNGX vs NTLA Comparison
Compare TNGX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NTLA
- Stock Information
- Founded
- TNGX 2014
- NTLA 2014
- Country
- TNGX United States
- NTLA United States
- Employees
- TNGX N/A
- NTLA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TNGX Health Care
- NTLA Health Care
- Exchange
- TNGX Nasdaq
- NTLA Nasdaq
- Market Cap
- TNGX 1.0B
- NTLA 1.2B
- IPO Year
- TNGX N/A
- NTLA 2016
- Fundamental
- Price
- TNGX $7.99
- NTLA $9.21
- Analyst Decision
- TNGX Strong Buy
- NTLA Buy
- Analyst Count
- TNGX 6
- NTLA 20
- Target Price
- TNGX $10.80
- NTLA $22.43
- AVG Volume (30 Days)
- TNGX 4.3M
- NTLA 11.1M
- Earning Date
- TNGX 11-04-2025
- NTLA 11-06-2025
- Dividend Yield
- TNGX N/A
- NTLA N/A
- EPS Growth
- TNGX N/A
- NTLA N/A
- EPS
- TNGX N/A
- NTLA N/A
- Revenue
- TNGX $66,501,000.00
- NTLA $57,528,000.00
- Revenue This Year
- TNGX $20.41
- NTLA $8.51
- Revenue Next Year
- TNGX N/A
- NTLA N/A
- P/E Ratio
- TNGX N/A
- NTLA N/A
- Revenue Growth
- TNGX 53.29
- NTLA 33.52
- 52 Week Low
- TNGX $1.03
- NTLA $5.90
- 52 Week High
- TNGX $9.70
- NTLA $28.25
- Technical
- Relative Strength Index (RSI)
- TNGX 49.39
- NTLA 30.06
- Support Level
- TNGX $7.12
- NTLA $12.15
- Resistance Level
- TNGX $8.17
- NTLA $13.69
- Average True Range (ATR)
- TNGX 0.74
- NTLA 1.51
- MACD
- TNGX -0.07
- NTLA -1.34
- Stochastic Oscillator
- TNGX 45.74
- NTLA 0.69
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.